In a recent article published in the Journal of Translational Medicine, a team of researchers from the College of Dental, Oral, and Craniofacial Sciences has unveiled a novel method to combat periodontal (gum) disease and potentially reduce the incidence of diabetes and obesity. This innovative approach centers around utilizing the common Type 2 diabetes drug,… Continue reading Common diabetes drug may treat gum disease and aid healthy aging
Day: December 28, 2023
FDA approves Voquezna for erosive esophagitis, gastroesophageal reflux disease
In a significant milestone, the U.S. Food and Drug Administration (FDA) has greenlit Phathom Pharmaceuticals’ revolutionary therapy, Voquezna (vonoprazan), heralding a new era in the treatment landscape for erosive esophagitis (EE) and gastroesophageal reflux disease (GERD) among adults. The nod comes on the heels of the PHALCON-EE Phase III trial, where Voquezna 20 mg showcased… Continue reading FDA approves Voquezna for erosive esophagitis, gastroesophageal reflux disease
Can new antibiotic chloropeptide defeat superbugs? Or will it join a long list of failed drugs?
In a world where even a simple infection poses a life-threatening risk, and a minor wound could lead to catastrophe, the effective treatment of diseases has become an increasingly challenging task for doctors. This is not a scenario from a science fiction movie but a real and pressing issue. For decades, antibiotics have been crucial… Continue reading Can new antibiotic chloropeptide defeat superbugs? Or will it join a long list of failed drugs?
Dependence-free pain relief
In recent times, attention has centered on the use of opioid medications, including morphine and related analgesics like hydrocodone. While considered a blessing for patients experiencing severe and acute pain, the potential for addiction and the risk of fatal overdose also pose a significant challenge. The opioid crisis, claiming thousands of lives annually in the… Continue reading Dependence-free pain relief
English 
Spanish